LAM Pilot Study With Imatinib Mesylate

NCT03131999 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Lymphangioleiomyomatosis

Interventions

DRUG: Imatinib Mesylate 400Mg Capsule
DRUG: Placebo - Capsule

Sponsor

Medical University of South Carolina

Collaborators

[object Object]